References
1. Stevens W, Shih T, Incerti D, Ton TGN, Lee HC, Peneva D, Macones GA, Sibai BM, Jena AB. Short-term costs of preeclampsia to the United States health care system. Am J Obstet Gynecol 2017; 217 : 237-248.e216.
2. Shennan AH, Green M, Chappell LC. Maternal deaths in the UK: pre-eclampsia deaths are avoidable. Lancet 2017; 389 : 582-584.
3. Steer P. The epidemiology of preterm labour. BJOG 2005;112 Suppl 1 : 1-3.
4. Brown MA, Magee LA, Kenny LC, Karumanchi SA, McCarthy FP, Saito S, Hall DR, Warren CE, Adoyi G, Ishaku S, (ISSHP) ISftSoHiP. Hypertensive Disorders of Pregnancy: ISSHP Classification, Diagnosis, and Management Recommendations for International Practice. Hypertension 2018;72 : 24-43.
5. Excellence NIfC. Hypertension in Pregnancy: diagnosis and management. . https://www.nice.org.uk/guidance/ng133, 2019.
6. Zhang J, Klebanoff MA, Roberts JM. Prediction of adverse outcomes by common definitions of hypertension in pregnancy. Obstet Gynecol2001; 97 : 261-267.
7. Milne F, Redman C, Walker J, Baker P, Black R, Blincowe J, Cooper C, Fletcher G, Jokinen M, Moran PA, Nelson-Piercy C, Robson S, Shennan A, Tuffnell A, Waugh J, Group PI. Assessing the onset of pre-eclampsia in the hospital day unit: summary of the pre-eclampsia guideline (PRECOG II). BMJ 2009; 339 : b3129.
8. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350 : 672-683.
9. Saffer C, Olson G, Boggess KA, Beyerlein R, Eubank C, Sibai BM, Group NS. Determination of placental growth factor (PlGF) levels in healthy pregnant women without signs or symptoms of preeclampsia.Pregnancy Hypertens 2013; 3 : 124-132.
10. Chaiworapongsa T, Romero R, Kim YM, Kim GJ, Kim MR, Espinoza J, Bujold E, Gonçalves L, Gomez R, Edwin S, Mazor M. Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia. J Matern Fetal Neonatal Med 2005; 17 : 3-18.
11. Chau K, Hennessy A, Makris A. Placental growth factor and pre-eclampsia. J Hum Hypertens 2017; 31 : 782-786.
12. Chappell LC, Duckworth S, Seed PT, Griffin M, Myers J, Mackillop L, Simpson N, Waugh J, Anumba D, Kenny LC, Redman CW, Shennan AH. Diagnostic accuracy of placental growth factor in women with suspected preeclampsia: a prospective multicenter study. Circulation 2013;128 : 2121-2131.
13. Excellence NIfC. PlGF-based testing to help diagnose suspected pre-eclampsia (Triage PlGF test, Elecysys immunoassay sFlt-1/PlGF ratio, DELFIA Xpress PlGF 1-2-3 test, and BRAHMS sFlt-1 Kryptor/BRAHMS PlGF plus Kryptor PE ratio) https://www.nice.org.uk/guidance/dg23, 2016.
14. Barton JR, Woelkers DA, Newman RB, Combs CA, How HY, Boggess KA, Martin JN, Kupfer K, Sibai BM, Trial PPTbRA. Placental growth factor predicts time to delivery in women with signs or symptoms of early preterm preeclampsia: a prospective multicenter study. Am J Obstet Gynecol 2019.
15. Parchem JG, Brock CO, Chen HY, Kalluri R, Barton JR, Sibai BM, Investigators PTbRATP. Placental Growth Factor and the Risk of Adverse Neonatal and Maternal Outcomes. Obstet Gynecol 2020.
16. Duhig KE, Myers J, Seed PT, Sparkes J, Lowe J, Hunter RM, Shennan AH, Chappell LC, group Pt. Placental growth factor testing to assess women with suspected pre-eclampsia: a multicentre, pragmatic, stepped-wedge cluster-randomised controlled trial. Lancet 2019;393 : 1807-1818.
17. Duckworth S, Chappell LC, Seed PT, Mackillop L, Shennan AH, Hunter R. Placental Growth Factor (PlGF) in Women with Suspected Pre-Eclampsia Prior to 35 Weeks’ Gestation: A Budget Impact Analysis. PLoS One2016; 11 : e0164276.
18. Frampton GK, Jones J, Rose M, Payne L. Placental growth factor (alone or in combination with soluble fms-like tyrosine kinase 1) as an aid to the assessment of women with suspected pre-eclampsia: systematic review and economic analysis. Health Technol Assess 2016;20 : 1-160.
19. Duhig KE, Seed PT, Myers JE, Bahl R, Bambridge G, Barnfield S, Ficquet J, Girling JC, Khalil A, Shennan AH, Chappell LC, Hunter RM. Placental growth factor testing for suspected pre-eclampsia: a cost-effectiveness analysis. BJOG 2019; 126 : 1390-1398.
20. Rana S, Powe CE, Salahuddin S, Verlohren S, Perschel FH, Levine RJ, Lim KH, Wenger JB, Thadhani R, Karumanchi SA. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia.Circulation 2012; 125 : 911-919.
21. Zeisler H, Hund M, Verlohren S. The sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia. N Engl J Med 2016; 374 : 1785-1786.
22. Cerdeira AS, O’Sullivan J, Ohuma EO, Harrington D, Szafranski P, Black R, Mackillop L, Impey L, Greenwood C, James T, Smith I, Papageorghiou AT, Knight M, Vatish M. Randomized Interventional Study on Prediction of Preeclampsia/Eclampsia in Women With Suspected Preeclampsia: INSPIRE. Hypertension 2019; 74 : 983-990.
23. McCarthy FP, Gill C, Seed PT, Bramham K, Chappell LC, Shennan AH. Comparison of three commercially available placental growth factor-based tests in women with suspected preterm pre-eclampsia: the COMPARE study.Ultrasound Obstet Gynecol 2019; 53 : 62-67.
24. Stepan H, Hund M, Gencay M, Denk B, Dinkel C, Kaminski WE, Wieloch P, Semus B, Meloth T, Dröge LA, Verlohren S. A comparison of the diagnostic utility of the sFlt-1/PlGF ratio versus PlGF alone for the detection of preeclampsia/HELLP syndrome. Hypertens Pregnancy2016; 35 : 295-305.
25. Benton SJ, Hu Y, Xie F, Kupfer K, Lee SW, Magee LA, von Dadelszen P. Angiogenic factors as diagnostic tests for preeclampsia: a performance comparison between two commercial immunoassays. Am J Obstet Gynecol 2011; 205 : 469.e461-468.
26. Cnossen JS, ter Riet G, Mol BW, van der Post JA, Leeflang MM, Meads CA, Hyde C, Khan KS. Are tests for predicting pre-eclampsia good enough to make screening viable? A review of reviews and critical appraisal.Acta Obstet Gynecol Scand 2009; 88 : 758-765.
27. Black C, Al-Amin A, Rolnik DL, Kane SC, Stolarek C, White A, da Silva Costa F, Brennecke S. Midpregnancy testing for soluble fms-like tyrosine kinase 1 (sFlt-1) and placental growth factor (PlGF): An inter-assay comparison of three automated immunoassay platforms.Placenta 2019; 86 : 11-14.
28. Cheng YKY, Poon LCY, Shennan A, Leung TY, Sahota DS. Inter-manufacturer comparison of automated immunoassays for the measurement of soluble FMS-like tyrosine kinase-1 and placental growth factor. Pregnancy Hypertens 2019; 17 : 165-171.
29. Duhig KE, Webster LM, Sharp A, Gill C, Seed PT, Shennan AH, Myers JE, Chappell LC. Diagnostic accuracy of repeat placental growth factor measurements in women with suspected preeclampsia: a case series study.Acta Obstet Gynecol Scand 2020.
30. Zeisler H, Llurba E, Chantraine FJ, Vatish M, Staff AC, Sennström M, Olovsson M, Brennecke SP, Stepan H, Allegranza D, Schoedl M, Grill S, Hund M, Verlohren S. Soluble fms-like tyrosine kinase-1 to placental growth factor ratio: ruling out pre-eclampsia for up to 4 weeks and value of retesting. Ultrasound Obstet Gynecol 2019; 53 : 367-375.
31. Rana S, Hacker MR, Modest AM, Salahuddin S, Lim KH, Verlohren S, Perschel FH, Karumanchi SA. Circulating angiogenic factors and risk of adverse maternal and perinatal outcomes in twin pregnancies with suspected preeclampsia. Hypertension 2012; 60 : 451-458.
32. Saleh L, Tahitu SIM, Danser AHJ, van den Meiracker AH, Visser W. The predictive value of the sFlt-1/PlGF ratio on short-term absence of preeclampsia and maternal and fetal or neonatal complications in twin pregnancies. Pregnancy Hypertens 2018; 14 : 222-227.
33. Dröge L, Herraìz I, Zeisler H, Schlembach D, Stepan H, Küssel L, Henrich W, Galindo A, Verlohren S. Maternal serum sFlt-1/PlGF ratio in twin pregnancies with and without pre-eclampsia in comparison with singleton pregnancies. Ultrasound Obstet Gynecol 2015;45 : 286-293.
34. Benton SJ, McCowan LM, Heazell AE, Grynspan D, Hutcheon JA, Senger C, Burke O, Chan Y, Harding JE, Yockell-Lelièvre J, Hu Y, Chappell LC, Griffin MJ, Shennan AH, Magee LA, Gruslin A, von Dadelszen P. Placental growth factor as a marker of fetal growth restriction caused by placental dysfunction. Placenta 2016; 42 : 1-8.
35. Gaccioli F, Sovio U, Cook E, Hund M, Charnock-Jones DS, Smith GCS. Screening for fetal growth restriction using ultrasound and the sFLT1/PlGF ratio in nulliparous women: a prospective cohort study.Lancet Child Adolesc Health 2018; 2 : 569-581.
36. Griffin M, Seed PT, Duckworth S, North R, Myers J, Mackillop L, Simpson N, Waugh J, Anumba D, Kenny LC, Redman CWG, Shennan AH, Chappell LC. Predicting delivery of a small-for-gestational-age infant and adverse perinatal outcome in women with suspected pre-eclampsia.Ultrasound Obstet Gynecol 2018; 51 : 387-395.
37. Griffin M, Seed PT, Webster L, Myers J, MacKillop L, Simpson N, Anumba D, Khalil A, Denbow M, Sau A, Hinshaw K, von Dadelszen P, Benton S, Girling J, Redman CW, Chappell LC, Shennan AH. Diagnostic accuracy of placental growth factor and ultrasound parameters to predict the small-for-gestational-age infant in women presenting with reduced symphysis-fundus height. Ultrasound Obstet Gynecol 2015;46 : 182-190.
38. Ukah UV, Mbofana F, Rocha BM, Loquiha O, Mudenyanga C, Usta M, Urso M, Drebit S, Magee LA, von Dadelszen P. Diagnostic Performance of Placental Growth Factor in Women With Suspected Preeclampsia Attending Antenatal Facilities in Maputo, Mozambique. Hypertension 2017;69 : 469-474.
39. Manriquez Rocha B, Mbofana F, Loquiha O, Mudenyanga C, Ukah UV, Magee LA, von Dadelszen P. Early diagnosis of preeclampsia using placental growth factor: An operational pilot study in Maputo, Mozambique. Pregnancy Hypertens 2018; 11 : 26-31.
40. Thadhani R, Hagmann H, Schaarschmidt W, Roth B, Cingoez T, Karumanchi SA, Wenger J, Lucchesi KJ, Tamez H, Lindner T, Fridman A, Thome U, Kribs A, Danner M, Hamacher S, Mallmann P, Stepan H, Benzing T. Removal of Soluble Fms-Like Tyrosine Kinase-1 by Dextran Sulfate Apheresis in Preeclampsia. J Am Soc Nephrol 2016; 27 : 903-913.
Table 1: Test performance of PlGF-based tests